Adaptimmune Sells Tecelra and Cell Therapy Assets to US WorldMeds for $85 Million Amid Financial Crisis
核心洞察
Adaptimmune announced the sale of its FDA-approved cell therapy Tecelra and two late-stage assets to US WorldMeds for up to $85 million as the company faces substantial solvency concerns.
The transaction includes $55 million upfront with potential additional payments of $30 million based on regulatory and commercial milestones, while Adaptimmune will cut its workforce by 62%.
Tecelra became the first T cell receptor (搜索) (TCR (搜索)) therapy approved in the U.S. for synovial sarcoma (搜索) in 2024, but generated only $4 million in first-quarter revenue against $29 million in R&D spending.
Struggling cancer cell therapy developer Adaptimmune announced Monday it will sell its approved medicine Tecelra and two late-stage assets to US WorldMeds in a deal worth up to $85 million, marking a dramatic retreat from commercial drug manufacturing as the company fights for survival.
The transaction serves as a lifeline for Adaptimmune, which initiated a strategic review in March due to "substantial doubt" about the company's continued solvency. Under the deal terms, Adaptimmune will receive $55 million upfront and could earn an additional $30 million based on achievement of regulatory and commercial milestones.
Workforce Reduction and Leadership Changes
The asset sale will trigger significant organizational changes at Adaptimmune. The company plans to cut its remaining workforce by 62% following the transaction, adding to a 29% headcount reduction earlier this year that was forecast to save $300 million over four years. All employees involved in commercialization and development of Tecelra, as well as the clinical-stage therapies lete-cel (搜索) and uza-cel, will transfer to US WorldMeds.
Key leadership departures include Chief Medical Officer Elliot Norry and Chief Commercial Officer Cintia Piccina, who will leave August 8, while Chief Scientific Officer Joanna Brewer will depart August 31.
Tecelra's Historic Approval Falls Short of Commercial Expectations
Tecelra gained Food and Drug Administration accelerated approval in 2024 for patients with synovial sarcoma (搜索), a type of solid tumor (搜索), becoming the first T cell receptor (搜索) (TCR (搜索)) cell therapy approved in the United States. This milestone distinguished it from the half dozen cell therapies using CAR-T technology that were approved earlier but have proven effective only in blood cancers (搜索).
Despite this groundbreaking achievement, Adaptimmune's innovation failed to translate into meaningful sales. The company reported just over $4 million in product revenue in the first quarter of 2025, dramatically overshadowed by nearly $29 million in research and development spending. Adaptimmune held $41 million in cash and equivalents at the end of March.
Market Response and Analyst Concerns
Adaptimmune shares plummeted by two-thirds following the announcement, trading at approximately 10 cents per share in afternoon trading. The dramatic stock decline reflects investor concerns about the company's financial viability despite the asset sale.
"After an extensive review of all strategic alternatives available to Adaptimmune we are convinced that this transaction represents the best path forward for Adaptimmune, our patients and stakeholders," said CEO Adrian Rawcliffe in a statement.
Mizuho Securities analyst Graig Suvannavejh characterized Adaptimmune's deal as a "net positive" given the company's solvency concerns but noted that the transaction size was "disappointing." Suvannavejh expressed continued uncertainty about whether the revenue from the deal and associated cost cuts would adequately address the company's liquidity concerns.
Retained Assets and Future Focus
Following the sale, Adaptimmune will retain possession of two T cell directed therapies currently in preclinical studies to support future human testing. This strategic decision suggests the company plans to maintain a presence in cell therapy development despite its retreat from commercial operations.